We are live on ! Find out more
VYNE icon

VYNE Therapeutics
VYNE

54 hedge funds and large institutions have $12.5M invested in VYNE Therapeutics in 2021 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 8 increasing their positions, 17 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

265% more call options, than puts

Call options by funds: $95K | Put options by funds: $26K

0.29% less ownership

Funds ownership: 1.56% → 1.27% (-0.29%)

16% less funds holding

Funds holding: 64 → 54 (-10)

38% less capital invested

Capital invested by funds: $20.1M → $12.5M (-$7.62M)

47% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 19

53% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 17

Holders
54
Holders Change
-10
Holders Change %
-15.63%
% of All Funds
0.83%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
10
Increased
8
Reduced
17
Closed
19
Calls
$95K
Puts
$26K
Net Calls
+$69K
Net Calls Change
-$39K

Top Buyers

Rank Fund Capital Flow
1
DA
DSC Advisors
Illinois
+$1.73M
2
Marshall Wace
Marshall Wace
United Kingdom
+$197K
3
GCP
GSA Capital Partners
United Kingdom
+$149K
4
Goldman Sachs
Goldman Sachs
New York
+$87.8K
5
VF
Virtu Financial
New York
+$79.8K

Top Sellers

Rank Fund Capital Flow
1
Franklin Resources
Franklin Resources
California
-$2.12M
2
6CM
683 Capital Management
New York
-$994K
3
Renaissance Technologies
Renaissance Technologies
New York
-$406K
4
Vanguard Group
Vanguard Group
Pennsylvania
-$227K
5
CM
CM Management
Florida
-$200K
Name Holding Trade Value Shares
Change 		Change in
Stake
SW
26
SkyOak Wealth
Michigan
$28K +$32.4K +1,511 New
Bank of New York Mellon
27
Bank of New York Mellon
New York
$27K – – –
CL
28
CSS LLC
Illinois
$26K – – –
Jane Street
29
Jane Street
New York
$26K +$30.2K +1,407 New
Ameriprise
30
Ameriprise
Minnesota
$22K -$12.5K -581 -33%
Commonwealth Equity Services
31
Commonwealth Equity Services
Massachusetts
$20K – – –
T. Rowe Price Associates
32
T. Rowe Price Associates
Maryland
$20K – – –
LPL Financial
33
LPL Financial
California
$18K -$21 -1 -0.1%
XT
34
XTX Topco
Cayman Islands
$17K +$20.3K +947 New
TRCT
35
Tower Research Capital (TRC)
New York
$8K +$3.43K +160 +53%
Russell Investments Group
36
Russell Investments Group
United Kingdom
$3K – – –
SPIA
37
Steward Partners Investment Advisory
New York
$2K -$2.15K -100 -48%
Federated Hermes
38
Federated Hermes
Pennsylvania
$2K – – –
Fidelity Investments
39
Fidelity Investments
Massachusetts
$2K – – –
First Manhattan
40
First Manhattan
New York
$2K – – –
Simplex Trading
41
Simplex Trading
Illinois
$2K +$2.34K +109 New
SWM
42
Spire Wealth Management
Virginia
$2K +$2.34K +109 New
PNC Financial Services Group
43
PNC Financial Services Group
Pennsylvania
$2K +$2.38K +111 New
MIFH
44
Migdal Insurance & Financial Holdings
Israel
$1K -$773 -36 -38%
Royal Bank of Canada
45
Royal Bank of Canada
Ontario, Canada
$1K -$537 -25 -37%
Northwestern Mutual Wealth Management
46
Northwestern Mutual Wealth Management
Wisconsin
$1K – – –
Osaic Holdings
47
Osaic Holdings
Arizona
$1K – – –
Rockefeller Capital Management
48
Rockefeller Capital Management
New York
$1K – – –
Wells Fargo
49
Wells Fargo
California
$1K +$1.74K +81 New
6CM
50
683 Capital Management
New York
– -$994K -39,744 Closed
1
2
3

VYNE Hedge Fund Activity: Q4 2021 in Review

54 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in VYNE Therapeutics (VYNE) for Q4 2021, worth a combined $12.5M — down 38% from $20.1M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of VYNE and 10 opened new positions — a net loss of 9 holders — while 17 trimmed existing stakes and 8 added.

The largest buyer was DSC Advisors, adding an estimated $1.73M. The largest seller was Franklin Resources, cutting an estimated $2.12M.

  • 54 institutional investors held VYNE Therapeutics (VYNE) as of Q4 2021, down from 64 in Q3 2021.
  • Funds reported $12.5M of VYNE Therapeutics stock for Q4 2021, down 38% quarter-over-quarter.
  • 10 funds opened new VYNE Therapeutics positions in Q4 2021 and 19 closed out, a net change of -9 holders.
  • The largest VYNE Therapeutics buyer in Q4 2021 was DSC Advisors, an estimated $1.73M added.
  • The largest VYNE Therapeutics seller in Q4 2021 was Franklin Resources, an estimated $2.12M sold.

Based on aggregated 13F filings for Q4 2021.